All News
Better at Predicting RA from MRI: Humans or Computers?
An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undiffer
Read Article
The future of lupus treatment is oral therapies?
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?
Read Article
AOSD: Young vs. Elderly Onset
Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
Read Article
Overview of treatment strategies in #Lupus #EULAR2023 #Rheumtwitter https://t.co/zL1nEDajsb
Christian Ammitzbøll RheumTweeter ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5
Dr. John Cush RheumNow ( View Tweet)
75 different biosimilars in Europe, and nearly 20 years since the journey started. @EMA_News has led the world on biosimilars #EULAR2023 @RheumNow https://t.co/LFs3FR9dfW
David Liew drdavidliew ( View Tweet)
Would you rather have Erosive hands OA or RA?
130+ EHOA and 370+ RA, dis duration > 10 yrs for both cohorts
📍EHOA associated w/ > pain & functional impairment
📍RA associated w/ > comorbidities
@RheumNow #EULAR23 POS0103 https://t.co/KdDG7E6PZw
Aurelie Najm AurelieRheumo ( View Tweet)
A model predicts development of PsA in PSO cohort at 1 yr w/ AUC 72.3
Risk factors:
✔️younger age
✔️male
✔️family hx of PSO
✔️back stiffness
✔️nail pitting,
✔️stiffness
✔️PGA
✔️bioDMARDs
5yr prediction model AUC 75
Promising but to be confirmed
@RheumNow #EULAR23 POS0019 https://t.co/boCYOH2sDS
Aurelie Najm AurelieRheumo ( View Tweet)
@RheumNow hard at work, shooting KOL videos, at #EULAR2023 https://t.co/C9n2218oeU
Dr. John Cush RheumNow ( View Tweet)
ANSWER cohort
Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs
✔️IL-6Ri is the lowest discontinued for lack of efficacy
✔️CTLA4-Ig is the lowest discontinued due to AEs
✔️Concomitant GC ⬆️30% drug discontinuation due to AEs
@Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4
Aurelie Najm AurelieRheumo ( View Tweet)
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8)
Use of TNFi & orthopedic implants associated w/ OAI risk
Mortality however similar in RA and non RA groups
@RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B
Aurelie Najm AurelieRheumo ( View Tweet)
Always great to have @EMA_News to come and to talk to us at #EULAR2023
Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍
@RheumNow https://t.co/hSutraUsFD
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
NYU's star rheumatologist, Dr. Jose Scher, wit on the fly at #EULAR2023 https://t.co/O9afiVHSV5
Dr. John Cush RheumNow ( View Tweet)
Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC?
Brief answer is no, but:
-PsA > tortuous capillaries vs. PSO & HC
-Abnormalities in PSO to be used as predictor of PsA?
TBC...
@RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Fluorescence optical imaging in early arthritis?
Nice images but not ready for clinics yet
Can not differentiate OA from RA & PsA
SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis
OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5
Aurelie Najm AurelieRheumo ( View Tweet)
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush RheumNow ( View Tweet)